Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections
Most Products Remain In Preclinical Development
Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: a look at Alzheimer’s drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk’s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.
SIGA chief scientific officer Dennis Hruby spoke with Scrip about how the company is developing its drug, Tpoxx, to address the monkeypox outbreak.
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.